Interpace (IDXG) CEO Burnell Receives RSUs; Surrenders Shares for Taxes

What Happened
Burnell Thomas W., CEO, President & Chairman of Interpace Biosciences (IDXG), received a large equity award on August 20, 2026: 1,966,763 restricted stock units (RSUs) were granted and vested upon grant and converted into the economic equivalent of shares. The filing also shows an additional grant of 554,018 derivative awards (subject to separate vesting terms). To satisfy tax withholding obligations, 581,718 shares were returned to the company (disposed) at $1.61 per share, totaling $936,566. The RSU awards have a $0 exercise price; the separate derivative award/options will vest in four equal annual installments beginning August 20, 2027 (per the filing).

Key Details

• Transaction date: August 20, 2026 (filing date the same day).
• Awards granted: 1,966,763 RSUs (vested upon grant) and 554,018 additional derivative awards.
• Tax withholding: 581,718 shares surrendered at $1.61/share = $936,566 paid to the issuer for taxes. Transaction codes: A = grant/award, M = conversion/exercise of derivative, F = tax withholding.
• Exercise/price: RSUs converted at $0 exercise price; no cash purchase.
• Shares owned after transaction: not specified in the Form 4 filing.
• Timeliness: filing lists the same transaction and report date (Aug 20, 2026) — appears timely.

Context
This was primarily an awarded-and-settled RSU grant, not an open-market purchase or discretionary sale. The surrender of shares was done to cover tax withholding (a common, routine outcome when large equity grants vest) rather than a market sale for cash proceeds. The additional 554,018 derivative awards/options are subject to future vesting (four annual installments starting Aug 20, 2027), so they are not immediately exercisable.